Abstract:OBJECTIVE:To understand the predominant β-lactamase genotypes and their carrying modes of Escherichia coli isolates in Zhejiang province, and the effects of β-lactam antibiotics on inducing or histidine kinase inhibitor closantel (CLO) on inhibiting the expression of β-lactamase genes.METHODS:Micro-dilution method and E-test were applied to measure the resistant rate and minimal inhibitory concentration (MIC) in E. coli isolates against β-lactam antibiotics. PCR and sequence analysis of PCR products were conducted to detect the β-lactamase genotypes and their carrying modes. Real-time fluorescent quantitative RT-PCR and β-lactamase confirmation test were performed to determine the influence of 1/4 MIC penicillin and cefotaxime, and CLO on the transcription and expression of β-lactamase genes in the resistant E. coli isolates.RESULTS:Among the 462 E. coli strains isolated in Zhejiang, 285 (61.7%) were resistant to penicillin, ampicillin, cefoxitin, cefotaxim and ceftazidime. In the 285 resistant isolates, the detection rate of TEM or CTX-M β-lactamase gene (83.2% or 75.1%) was significantly higher than that of KPC, SHV or OXA β-lactamase gene (1.4%-10.2%) (P<0.01) and the carrying rate of two or more β-lactamase genes (68.8%) was also significantly higher than that of single β-lactamase gene (31.2%) (P<0.01), and 61.4% of the resistant isolates carried TEM+CTX-M genes (P<0.01). Except KPC gene, 1/4 MIC of cefotaxim and penicillin induced a rapid increase of TEM-mRNA, CTX-M-mRNA, SHV-mRNA or OXA-mRNA levels (P<0.01), but 50-500 µg/ml CLO inhibited these levels (P<0.01). After pre-treatment with 100 µg/ml CLO, 82.8%-85.6% of the resistant isolates became sensitive to β-lactam antibiotics (P<0.01), while the detection rate of β-lactamases was also decreased from 95.1% to 16.1% (P<0.01).CONCLUSION:TEM and CTX-M are the predominant β-lactamase genotypes in E. coli isolates in Zhejiang and TEM+CTX-M is the predominant carrying mode of β-lactamase genes. Low concentrations of β-lactam antibiotics can up-regulate the expression levels of β-lactamase genes in E. coli through bacterial two-component signaling systems, but this effect can be inhibited by CLO, a histidine kinase inhibitor.

Progress in Pharmacokinetics/pharmacodynamics of Β-Lactam/β-lactamase Inhibitor Combination

Progress on pharmacokinetics/pharmacodynamics of antimicrobial agents

Metabolic Analyses Revealed Time-Dependent Synergistic Killing by Colistin and Aztreonam Combination Against Multidrug-Resistant Acinetobacter Baumannii

Efficacy of synergistic antibiotic combinations against KPC-2 carbapenemase producing Klebsiella pneumoniae strains

In vitro Effect of the Combination of Aztreonam and Amoxicillin/Clavulanic Acid Against Carbapenem-Resistant Gram-Negative Organisms Producing Metallo--Lactamase

Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter baumannii .

Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria

[Predominant Β-Lactamase Genotypes of Escherichia Coli Isolates and Induction and Inhibition Mechanisms of Β-Lactamase Gene Expression].

In Vitro and in Vivo Activities of a Novel Β-Lactamase Inhibitor Combination Imipenem/xnw4107 Against Recent Clinical Gram-negative Bacilli from China.

Antibacterial activity study of several β-lactam/β-lactamase inhibitor combinations in vitro

Influence of β-lactam pharmacodynamics on the systems microbiology of gram-positive and gram-negative polymicrobial communities

Dynamic Effect of β-Lactam Antibiotic Inactivation Due to the Inter- and Intraspecies Interaction of Drug-Resistant Microbes

Antibacterial Pharmacokinetics/pharmacodynamics and Optimizing Treatment of Nosocomial Pneumonia

Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

Evaluation of the in vitro synergy of polymyxin B-based combinations against polymyxin B -resistant gram-negative bacilli

In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae.

Synthesis and Evaluation of Carbapenem/Metallo-β-Lactamase Inhibitor Conjugates

[A study of beta-lactamase activity of mycobacteria and clinical trial of penicillin/beta-lactamase inhibitor combinations in the treatment of drug-resistant Mycobacterium tuberculosis]

Study of In Vitro Synergistic Bactericidal Activity of Dual β-Lactam Antibiotics Against KPC-2-Producing Klebsiella pneumoniae .

What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review

Improved synthesis and evaluation of preclinical pharmacodynamic parameters of a new monocyclic β-lactam DPI-2016